Is There a Role for Thromboprophylaxis in Sickle Cell Patients with Central Venous Access Devices?
Stéphanie Forté(University Health Network), Kevin H.M. Kuo(University Health Network), Shivani Bhat(University of Limerick), John Aneke(University Health Network), Olivia Pestrin(University Health Network), Nafanta Fadiga(University Health Network), Richard Ward(University of Tennessee Health Science Center)
Cited by 2
Related Papers
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Online haemodiafiltration: definition, dose quantification and safety revisited
|Nephrology Dialysis Transplantation|2013|256
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162